Skip to content
UPXI

UPEXI, INC.

UPEXI, INC. Q4 FY2026 earnings call

September 17, 2026 · fiscal period ended 2026-06

EPS · actual vs est

/ $-0.11

Revenue · actual vs est

/ $4.2M
Ask about this call

Summary

Generated 2026-09-17

Management highlights

  • Treasury Strategy & Capital Raises: Launched the Solana Treasury Strategy in April 2025, raising $100 million via equity and $200 million via convertible notes in July 2025 to bootstrap the strategy.
  • Balance Sheet Strengthening: Increased cash position by 65% to $5.8 million using ATM proceeds; extinguished roughly $20 million in debt in June; refinanced credit facility post-quarter, reducing interest rates from 11.5% to 7.5% and lowering collateral requirements.
  • Operational Efficiency: Completed efficiency initiatives including outsourcing manufacturing, warehousing, and logistics; reduced full-time employees from 59 to 10 to create a predictable expense profile.
  • Staking Revenue Outlook: Management expects staking revenue to exceed ongoing cash expenses starting in the current quarter ending September 30, 2026.
  • Solana Market Position: Highlighted Solana’s strong fundamentals, including a 48% YoY increase in stablecoin supply, over $5 billion in tokenized equity trading volume (97% market share), and low median transaction fees of 0.04 cents.
  • Institutional Adoption: Noted significant institutional partnerships and announcements from entities such as SoFi, Western Union, State Street, Google Cloud, and Amazon Web Services, signaling growing integration of Solana into traditional financial infrastructure.
View in transcript ↓

Segment performance

UPEXI operates as a digital asset treasury company with Solana (SOL) as its primary asset. For the fiscal year ended June 30, 2026, the company reported total assets of $180.1 million, consisting of approximately $5.8 million in cash and $165.3 million in Solana holdings. The treasury held approximately 2.34 million SOL tokens with an average cost basis of $154 per token. Digital asset revenues for the year were $17.4 million, derived from staking yields equivalent to approximately 135,000 SOL tokens. General administrative expenses were $26.4 million, while stock-based compensation was $21.9 million and interest expense was $13.6 million. The company recorded a net loss of $246.1 million ($3.87 per share), driven primarily by $195.1 million in unrealized losses and $11.7 million in realized losses on digital assets.

View in transcript ↓

Guidance

  • Expense Coverage: Management guides that staking revenue is expected to more than cover ongoing cash expenses beginning in the quarter ending September 30, 2026.
  • Market Outlook: Maintains an optimistic long-term view, anticipating a return to a bull market which will drive value creation and premium returns for Solana holdings.
  • Capital Allocation: No specific numerical forward guidance provided; emphasis remains on creative capital allocation strategies, including potential debt restructuring or extension negotiations to maximize shareholder value.
View in transcript ↓

Risks

  • Digital Asset Volatility: Significant unrealized losses ($195.1 million) and realized losses ($11.7 million) highlight the risk associated with Solana price fluctuations.
  • Negative Equity: Total stockholders' equity is negative $53.8 million, reflecting the impact of digital asset losses and strategic execution changes.
  • Debt Obligations: Presence of convertible notes and short-term debt creates liquidity and dilution risks if not managed effectively through conversion or refinancing.
  • Market Timing Risk: Reliance on future crypto market upturns for profitability exposes the company to prolonged bear market scenarios.
View in transcript ↓

Q&A highlights

Q: Brian Kinslinger asked about yield maximization avenues and top priorities for FY2027. / A: CSO Brian Rudick stated they are actively exploring low-risk, recurring yield opportunities but found some less attractive during the bear market. He noted these opportunities will likely improve as the crypto market recovers, emphasizing patience until conditions become favorable.

Q: Kinslinger questioned why management calculates MNAV assuming convertibility of in-kind notes despite the stock price being below strike prices. / A: CEO Allan Marshall refused to speculate on Solana price movements, citing extreme volatility (e.g., dropping from $234 to $82 in 150 days). He maintained consistency with prior reporting assumptions and noted that high implied volatility suggests a still-high probability of conversion, avoiding speculative accounting treatments.

Q: Gareth Garchetta asked about the capital allocation framework following a private placement that retired debt at a discount, comparing it to the buyback program. / A: Marshall emphasized creativity in capital allocation, seeking deals that benefit both investors and shareholders. He cautioned against raising capital too aggressively near NAV without considering downside risk, aiming for accretive raises only when aligned with a future Solana price recovery.

Q: Garchetta inquired if the Blueprint delegation was part of the Hivemind deal and how much treasury would shift to Blueprint. / A: CFO Andrew Norstrud clarified that no treasury shift was occurring; Blueprint is one of several validators providing competitive rates. CEO Marshall explained the Blueprint partnership deepened ties with Hivemind to expand UPEXI’s footprint into Asian markets, leveraging their platform access rather than altering validator economics.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$-0.11
Revenue$4.2M

Transcript

September 17, 2026

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.